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Determination of 
appropriate clomipramine 
dosage among depressed 
African outpatients in Dar 
es Salaam, Tanzania
GP KILONZO, SF KAAYA, JK RWEIKIZA*, M 
KASSAM, G MOSHI
SUMMARY
In an open clomipramine dose finding study, 33 de­
pressed indigenous African outpatients were randomly 
assigned to two regimens of treatment with 125 mg and 
75 mg oral medications daily. At the end of eight weeks 
of treatment, 16 patients (48,5 pc) were on the 75 mg 
regime, and 17 (54,8 pc) were on 125 mg.
Analysis of depression scores cm the Beck-Rafaelsen 
scale indicated improvements of depression in both 
regimes of equal magnitude. Analysis of variance 
showed no statistically significant difference on dose 
response between the two regimes. The higher doses, 
however, were associated with more drowsiness and 
tremulousness.
It is suggested that Black African patients respond to 
tricyclic antidepressants in much lower doses than 
those recommended in Western textbooks. It is also 
apparent that side effects of tricyclic antidepressants, 
which have been implicated in non-compliance to 
medication, could be avoided without compromising 
treatment outcome.
INTRODUCTION
Ethnic and racial factors have been implicated as deter­
minants to the outcome of psychotropic medication.12 
Ethnic differences in response to such medication 
affects dosage requirements and risk of potential side 
effects. Looking specifically at antidepressant medica-
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tion, significantly lower treatment and maintenance 
dosage requirements have been noted in Orientals 
when compared to Occidentals.3 Patients were noted to 
respond equally to antidepressants regardless of the 
dosage chosen in Asia and other developing countries 
as opposed to the Occident where higher doses were 
effective.4
The majority of studies on Black populations have 
been done in the Americas and West Indies,5 6 and 
tended to support the impression that Black patients 
with depression may respond to much lower doses of 
antidepressants than their Caucasian counterparts. This 
impression has also been supported by pharmacokinet­
ics data, which indicated that Black patients have 
significantly higher nortriptyline plasma levels than 
White patients.7 This finding may indicate different 
rates of metabolism which may be the explanation for 
the more rapid response among Blacks as well as 
response at lower dosage.
The different pharmacokinetics of drugs are thought 
to be related to a combination of genetic and environ­
mental factors. Genetic differences in acetylation and 
oxidation have been implicated by Clark,8 and this 
could explain the ethnic variability in dose response. 
Underlying psychogenic and biochemical factors in the 
aetiology of mental illness may also vary in different 
cultures, resulting in variations in symptomatology.9
The relevance of such differences to clinical prac­
tice, depends on the type of drug and costs involved. 
Drugs with narrow margins of safety, such as antide­
pressants, where unpleasant side effects may hamper 
compliance, make ethnic variability in response to 
treatment an important factor. Where funds for medical 
services are scarce, and purchasing of psychotherapeutic 
medications competes with drugs for highly prevalent 
infective conditions, as is the case in most developing 
countries, it is crucial to establish appropriate lowest 
effective dosage and not to employ the dosage estab­
lished in Western cultures.
This study was designed to investigate whether 
Black depressed patients in Dar es Salaam could be 
successfully treated with clomipramine at lower doses 
than those in the West. The objectives of the study were 
to determine whether indigenous (Black) African pa­
tients suffering from depressive illness meeting the 
DSM-111 (American Psychiatric Association, 1980) 
criteria for condition responded to a lower dose of
clomipramine than that recommended in standard text­
books, and whether such responses would be similar to 
those obtained with higher doses of the drug. The study 
also hoped to compare reported side effects amongst 
patients on a higher and lower dose regime of 
clomipramine. Such information would be useful in the 
training of mental health workers on appropriate dos­
age requirements to ensure not only adequate symptom 
relief, but also to mitigate against unpleasant side 
effects that may result in poor compliance.
MATERIALS AND METHODS
An open titration study design was used. Consecutive 
patients presenting with depression at new patients 
clinics of the Department of Psychiatry of Muhimbili 
Medical Centre over a nine month period beginning in 
April 1988 were recruited.
Inclusion criteria were:
1. A DSM- 111 diagnosis for major depressive disor­
der.
2. Absence of any drug treatment for the current 
episode.
3. Indigenous African patient.
4. Age range between 16 and 70 years.
Patients were excluded if;
1. They had any cardiovascular, renal, or hepatic 
disorder.
2. The patient suffered from seizure disorder.
3. The patient was pregnant or planning pregnancy in 
the near future.
4. The patient suffered from or had a history of glau­
coma.
5. There was a real possibility of poor compliance.
6. Neuroleptic medication would be necessary in ad­
dition to clomipramine.
Patients were withdrawn from the study if any of the 
exclusion criteria occurred during the course of treat­
ment.
Informed consent was obtained prior to inclusion of 
the patients into the study and patients were random­
ized to the two dose regimens (Table I). On entry into 
the study, and at each follow up attendance, the pa­
tients’ mood was rated using the Beck-Rafaelsen scale 
for depression. At follow up, if there was no change in 
more than half of the depressive scales listed, the 
patient was moved to the next higher dose in the 
particular regime.
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Table I: Dose regimens A and B and time intervals 
for follow up visits.
Visits Time interval from 
previous visit (days)
Dose A 
mg
Dose B 
mg
1 0 25 25
2 3 50 75
3 3 75 125
4 14 75 125
5 14 75 125
6 30 75 125
Four doctors were involved in the diagnosis of 
depression and rating of mood. One was a qualified 
psychiatrist and the rest residents in psychiatry. The 
principle investigator (GPK) counter checked all the 
diagnosis of depression.
Data analysis: Data entry and cleaning was done 
using Lotus 1-2-3 version l.Oformat before translation 
to SPSS-PC 2.0 for statistical analysis. Analysis of 
variance was carried out on the depression rating 
scores according to drug dosage during various visits.
Reliability of the depression scale: The Beck- 
Rafaelsen scale was studied by all the raters two weeks 
prior to the onset of the study. A day was spent 
clarifying issues and the scale tested out individually 
on patients by each of the raters prior to the second 
meeting. The initial 10 consecutive patients were rated 
separately by the principle investigator and a second 
rater to establish inter-rater reliability. Following this 
every fifth patient seen by each of the raters was re- 
rated by the principle investigator. An overall 95,1 pc 
agreement was achieved between raters and the prin­
ciple investigator, ranging from between 94,6 pc and 
96 pc.
RESULTS
Sixty four depressed patients meeting DSM-111 crite­
ria for major depressive disorder with melancholia 
were seen and followed up over a two month period. Of 
these, 39 had no florid psychotic symptoms that would 
necessitate medication with neuroleptic drugs. Five 
patients refused to give consent and were not included 
in the study, while one patient was withdrawn due to 
non-compliance (failed to attend second follow up 
visit). Results are therefore reported on 33 patients, 12 
females and 21 males.
There was no significant difference in the mean ages 
of male and female patients seen, 34,1 and 37,9 years 
respectfully (Table II). Just over a fifth (21,2 pc) of all
the patients reported a family history of depressive 
illness, 12,1 pc reported a history of alcohol abuse, 
while 3 pc admitted abuse of other drugs. Characteris­
tically, females tended to report a significantly longer 
duration of illness than males; 55,8 weeks as compared 
to 25,5 weeks (p = 0,03). No significant difference was 
noted in improvement, as judged by depression scores, 
when men and women were compared.
Table II: Distribution o f the sample by sex and mean 
age within the two regimes.
Sex & age Dose regime Total
A B
Males 11 10 21
Females 5 7 12
Total (pc) 48,5 51,5 100
Mean age (years) 37,7 31,2 34,4
When the patients assigned to dose regimes A and B 
were compared, no significant differences in age and 
sex distribution was noted, nor was there any difference 
in their mean depression scores on the first visit.
Due to the severity of depressive symptoms, three 
patients (9,1 pc) were started on 50 mg of clomipramine 
at the first visit. A decrease in depression score was 
noted as anticipated at each consecutive follow up visit, 
a larger drop occurring between one to five weeks of 
treatment (Table III). The largest decrease in mean 
depression score of about 3,5 pc was noted between the 
first and third week of treatment. At the end of the study 
period, 48,5 pc of patients were on 75 mg of 
clomipramine, while 51,5 pc of patients were on 125 
mg.
Table III: Proportion o f  patients on different doses 
o f clomipramine and mean depression score for the 
various visits.
Dose (mg) Patients on various doses at each visit
Visits 1 2 3 4 5 6
25 90,9 
50 9,1 36,7 10,7 3,0
75 63,3 42,9 45,5 48,5 48,5
125 46,4 51,5 51,5 51,5
Mean depression 18,7 17,6 14,1 11,5 8,96 7,17
score
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Analysis of mean depression scores measured dur­
ing each follow up visit at different drug dosage levels 
revealed reduction of scores with time at doses between 
50 mg and 125 mg of clomipramine (Table IV). It was 
interesting that patients showing good responses to 
treatment on 50 mg of clomipramine, continued to 
show such improvement when maintained at that dose 
level on the third (four patients) and fourth (one patient) 
visits. No significant differences were noted in im­
provements of depression scores at 50 mg as compared 
to higher doses.
Table TV: Mean depression score during visits and 
different dosage levels.
Visits
Dosage level (mg) 
25 50 75 125 P
1 19,0 11,0 <0,5
2 18,6 17,2 <0,5
3 17,3 14,6 13,4 <0,5
4 14,0 11,8 11,1 <0,5
5 9,1 8,8 <0,5
6 7,9 6,5 <0,5
Reduction of depressive symptoms, as evidenced by 
improvements in the depression scores, occurred in 
patients on both treatment regimes (Table V). In both 
regimes, a large drop in depression scores was noted 
between the second and third follow up visits. There 
was no statistical difference in dose response, as mea­
sured by depression scores over time, of patients in the 
two treatment groups.
Table V: Mean depression scores during visits 
comparing regimes A and B.
Visits Regime A Regime B p
1 19,46 18,13 <0,1
2 17,8 17,5 <0,5
3 13,8 13,2 <0,1
4 10,4 11,1 <0,1
5 7,0 7,6 <0,1
6 6,13 5,87 <0,1
No clear pattern emerged when the side effects 
experienced by patients in the two regimes during the 
various follow up visits, was investigated. In total, 15 
patients (45,5 pc) reported minor side effects following 
the first visit, while 26 patients (72,7 pc) reported side
effects at the last visit. During the last visit, drowsiness 
was the most common complaint by patients on the 
higher dose regime followed by tremour, while consti­
pation was reported more often by patients on the lower 
dose regime (Table VI). Although the number of pa­
tients reporting the different side effects were too small 
for valid statistical significance testing, the numbers 
reporting side effects were surprising, given that the 
doses used for this study were lower than those recom­
mended by Western text books.
Table VI: Percentages o f patients with side effects at 
first and sixth visit by the two treatment regimes.
Side effect Visit 1 
Regime 
A B
Visit 6 
Regime 
A B
Dry mouth 15,25 9,1 0,0 0,0
Constipation 6,12 0,0 21,2 0,0
Tremor 0,0 3,0 0,0 9,1
Ataxia 6,1 0,0 0,0 0,0
Drowsiness 6,1 0,0 15,4 27,3
DISCUSSION
The small sample size in this study limits any broad 
generalizations, though as a preliminary inquiry into 
antidepressant dosage requirements of depressed Black 
African patients, it does reveal some information that 
supports anecdotal observations that depressed pa­
tients in this setting appear to respond to much lower 
doses of antidepressants than those recommended in 
textbooks.
These findings are especially sighificant given that 
depressed patients represent a large proportion of pa­
tients seen at primary health care levels. Hannah10 
identified depression in 29 pc of 1100 patients, attend­
ing primary care facilities in three rural dispensaries in 
Tanzania, while depressed patients represent 18 pc of 
patients seen by community mental health teams in Dar 
es Salaam.11 Holmes and Speight12 noted that 48 pc of 
consecutive first attenders at a referral general medical 
clinic of a consultant hospital in Tanzania, primarily 
suffered from psychosocial conditions, a large propor­
tion of which were depressive disorders. The use of 
lower dosesofantidepressantmedications wouldthere- 
fore contribute to a significant reduction in the cost of 
treatment.
Since the efficacy of clomipramine in depression is 
well established, and the main objective of the study
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was to find out if lower doses were as effective as usual 
recommended doses, it was felt that an open trial would 
be sufficient at a preliminary inquiry into the subject of 
antidepressant dose requirements. The study relied on 
patients’ and relatives’ reports far assessment of com­
pliance. Measurement of plasma clomipramine levels 
was not feasible because of scarcity of resources. 
However, consistency in the course of the clinical 
picture, suggested that compliance was good.
The results demonstrated that 75 mg clomipramine 
was as effective as 125 mg per day in the treatment of 
depression. There was also internal consistency of the 
results in that responses to the antidepressant effects of 
clomipramine, as evidenced by falling depression scores 
were in keeping with the clinical course of depression 
on tricyclic antidepressants. Although the small size of 
the sample made it difficult to interpret the significance 
of the occurrence of side effects, it appeared that higher 
doses were associated with more tremour while lower 
doses were associated with complaints of constipation.
As these results suggest, response to tricyclic antide­
pressants among Black Africans could occur with as 
low as 50 mg of clomipramine per day, and mainte­
nance of this dose could result in further improvement 
of depressive scores as demonstrated by the four pa­
tients who were maintained on a daily dose of 50 mg. 
It might be possible to apply a very gradual increase in 
dose, carefully titrating clinical response with side 
effects, and in this way achieving better compliance 
without sacrificing clinical response.
The demonstration of response to antidepressant 
medication at lower than recommended doses in Black 
Africans is in keeping with studies done in Black 
depressed patients in North America5 7 and the West 
Indies.6 Socio-cultural factors in the west and the West 
Indies are very different from those in Tanzania. Bio­
logical factors (constitution and genetic) may explain 
the observed lower dose requirements among Black 
people. This aspectrequiresfurther studies which should 
include determination of plasma levels of clomipramine 
and enzymatic activity related to the metabolism of the 
drug in Black patients.
In conclusion, this study generally supports earlier 
findings of lower antidepressantrequirements for Blacks 
compared to Caucasian patients suffering from depres­
sion. Given the unpleasant side effects of antidepres­
sant medication, and the effect this might have on drug 
compliance, the authors advice that, Black African 
depressed patients should be started on low doses of 
antidepressants, which should then be gradually ti­
trated against side effects, to arrive at an effective dose
with fewer side effects.
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